Company webinar

Avecho Biotechnology (ASX:AVE)

Watch our webinar with Avecho Biotechnology, featuring CEO Dr Paul Gavin. A presentation followed by live Q&A with the audience.

Date
June 5, 2026
Time
Where
Online
Entry
Free
Dr Paul Gavin
Dr Paul Gavin
CEO, Avecho Biotechnology (ASX:AVE)

About the company

Avecho Biotechnology Limited develops and commercialises innovative pharmaceutical products using its proprietary drug delivery system called TPM, which is proven to enhance the absorption of drugs in the body. Avecho’s lead asset is a proprietary cannabidiol (“CBD”) TPM soft-gel capsule currently undergoing Phase III clinical development for the treatment of insomnia. The product is targeting a unique registration opportunity with the Therapeutic Goods Administration (TGA) in Australia and is already the focus of a licensing deal with Sandoz, the largest generic pharmaceutical company in the world.

Key topics

  • Avecho’s proprietary Cannabidiol TPM capsule with increased absorption
  • Clinical insomnia indication market and Phase III trial design
  • Unique regulatory and commercial opportunity
  • Pharmaceutical licensing deal with Sandoz
  • Phase III interim analysis result in June - next steps beyond

Watch the recording

More webinars

All webinars →

Go beyond the presentation

Management tells one side of the story. Sharewise clients get independent research and Advisor access across ASX, US and global markets.

Explore our services →